Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline plc : GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2011 | 02:58pm CET

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Tuesday 20 December 2011, London UK

Agreement reached to divest brands in USA and Canada to Prestige Brands Holdings, Inc. for £426m ($660m). Process continues for divesting brands outside these markets and global rights for alli

In February 2011 GSK announced its intention to divest non-core Consumer Healthcare OTC products predominantly in the United States and Europe with aggregate annual sales of approximately £500 million. The proposed divestment is designed to realise value for shareholders and simplify GSK's Consumer Healthcare business and allow it to focus on its priority brands and markets.

Brands in USA and Canada
GSK today announced that it has reached agreement to divest the previously identified non-core OTC brands in the United States and Canada to Prestige Brands Holdings, Inc. for £426 million ($660 million) in cash.

The brands being divested include BC, Goody's, Beano, Ecotrin, Fiber Choice and Tagamet and generated sales of approximately £134 million in 2010 and £98 million in the first 9 months of 2011. It is expected the divestment will complete in H1 2012, subject to regulatory approvals.

The net cash proceeds from the transaction are expected to be approximately £242 million. These will be returned to shareholders during 2012.

The net profit on disposal of the assets (including all transaction costs) is estimated to be approximately £240 million (pre-tax), £145 million (post-tax). The pre-tax profit will be recorded in Other Operating Income following completion of the disposal.

Brands outside USA and Canada and global rights for alli
The process for divestment of the remaining brands continues. These assets generated sales of approximately £400 million in 2010 and £262 million in the first nine months of 2011. The company also plans to return any net proceeds from the sale of these brands to shareholders.

GSK's Chief Financial Officer, Simon Dingemans said: "The disposal of our non-core consumer brands is about realising attractive value for shareholders as well as simplifying our ongoing Consumer business and allowing it to focus on its priority brands and markets. I am pleased that we have achieved such a good result for our US and Canadian assets, especially in such difficult market conditions. Active discussions continue with other potential buyers for the remaining assets."

About Prestige Brands Holdings, Inc.
Prestige Brands Holdings, Inc. is engaged in the marketing, sale and distribution of brand name over-the-counter healthcare products and household cleaning products. Its products are sold in chain and independent drug stores, supermarkets, and mass merchandisers throughout the United States and Canada, and selected international markets. The Company is headquartered in Irvington, New York, with business offices in Jackson, Wyoming.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

Stephen Rea

+44 (0) 20 8047 5502

(London)

Sarah Spencer

+44 (0) 20 8047 5502

(London)

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Kevin Colgan

+1 919 483 2839

(North Carolina)

Mary Anne Rhyne

+1 919 483 2839

(North Carolina)

Sarah Alspach

+1 919 483 2839

(Washington, DC)

Jennifer Armstrong

+1 919 483 2839

(Philadelphia)

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+ 44 (0) 20 8047 5503

(London)

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2010.



share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
07:10a GLAXOSMITHKLINE : *goldman raises glaxosmithkline price target to 1850 pence - '..
01/23 GLAXOSMITHKLINE : *berenberg cuts glaxosmithkline price target to 1850 pence - '..
01/21 GLAXOSMITHKLINE : Cci approves aspen global-glaxosmithkline deal
01/20 GLAXOSMITHKLINE : *jefferies raises glaxosmithkline price target to 1780 pence -..
01/19 ASTRAZENECA : Luke Miels appointed President, Global Pharmaceuticals, GSK | GSK
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
01/19 GLAXOSMITHKLINE : *deutsche bank raises glaxosmithkline price target to 1800 pen..
01/19 TOP NEWS : GlaxoSmithKline Poaches AstraZeneca's Miels To Lead Pharma
01/19 GLAXOSMITHKLINE : Luke Miels appointed President, Global Pharmaceuticals, GSK
More news
Sector news : Pharmaceuticals - NEC
08:54pDJMARKET SNAPSHOT : Dow Makes A Run At Elusive 20,000 Amid Earnings Fusillade
07:24p MORGAN STANLEY : Toronto biotech raises $200 million ahead of ADHD drug decision
01:30pDJJOHNSON & JOHNSON : Revenue Rises But Forecast Disappoints
12:35a U.S. reaches settlement with Endo on pay-for-delay charges
01/20 European shares ease ahead of Trump inauguration
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:01a We're Hesitant On AnaptysBio's IPO
01/23 Visterra Seeks $50 Million IPO
01/23 3 Stocks Offering Yields To Help Retirees Pay Current Bills
01/20 Why Gilead Is Undervalued
01/20 Pharma bigwigs acknowledge challenges with perceptions of pricing as Trump pr..
Advertisement
Financials ( GBP)
Sales 2016 27 604 M
EBIT 2016 7 238 M
Net income 2016 2 340 M
Debt 2016 13 792 M
Yield 2016 5,31%
P/E ratio 2016 31,93
P/E ratio 2017 18,56
EV / Sales 2016 3,22x
EV / Sales 2017 2,99x
Capitalization 74 977 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,7  GBP
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-0.99%93 604
JOHNSON & JOHNSON-1.13%309 896
ROCHE HOLDING LTD.0.39%200 025
PFIZER INC.-3.14%190 910
NOVARTIS AG-4.32%183 809
MERCK & CO., INC.4.99%170 419
More Results